444 related articles for article (PubMed ID: 16973562)
1. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
Sagar M; Wu X; Lee S; Overbaugh J
J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
[TBL] [Abstract][Full Text] [Related]
2. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
3. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
[TBL] [Abstract][Full Text] [Related]
4. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
5. N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies.
Teeraputon S; Louisirirojchanakul S; Auewarakul P
Viral Immunol; 2005; 18(2):343-53. PubMed ID: 16035946
[TBL] [Abstract][Full Text] [Related]
6. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
[TBL] [Abstract][Full Text] [Related]
7. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
[TBL] [Abstract][Full Text] [Related]
8. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
Quiñones-Kochs MI; Buonocore L; Rose JK
J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
[TBL] [Abstract][Full Text] [Related]
9. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
Laird ME; Igarashi T; Martin MA; Desrosiers RC
J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
[TBL] [Abstract][Full Text] [Related]
10. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
12. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
Saunders CJ; McCaffrey RA; Zharkikh I; Kraft Z; Malenbaum SE; Burke B; Cheng-Mayer C; Stamatatos L
J Virol; 2005 Jul; 79(14):9069-80. PubMed ID: 15994801
[TBL] [Abstract][Full Text] [Related]
13. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.
Etemad B; Fellows A; Kwambana B; Kamat A; Feng Y; Lee S; Sagar M
J Virol; 2009 Oct; 83(19):9694-708. PubMed ID: 19625411
[TBL] [Abstract][Full Text] [Related]
15. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.
Silver ZA; Dickinson GM; Seaman MS; Desrosiers RC
J Virol; 2019 May; 93(10):. PubMed ID: 30842322
[TBL] [Abstract][Full Text] [Related]
16. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
Cao J; Sullivan N; Desjardin E; Parolin C; Robinson J; Wyatt R; Sodroski J
J Virol; 1997 Dec; 71(12):9808-12. PubMed ID: 9371651
[TBL] [Abstract][Full Text] [Related]
17. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
19. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
20. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
Chohan B; Lang D; Sagar M; Korber B; Lavreys L; Richardson B; Overbaugh J
J Virol; 2005 May; 79(10):6528-31. PubMed ID: 15858037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
